Cargando…

PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension

Cardiopulmonary exercise testing and pulmonary function test are important methods for detecting human cardio-pulmonary function. Whether they could screen vasoresponsiveness in idiopathic pulmonary artery hypertension (IPAH) patients remains undefined. One hundred thirty-two IPAH patients with comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Ci-Jun, Qiu, Hong-Ling, Wu, Chang-Wei, He, Jing, Yuan, Ping, Zhao, Qin-Hua, Jiang, Rong, Wu, Wen-Hui, Gong, Su-Gang, Guo, Jian, Zhang, Rui, Liu, Jin-Ming, Wang, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647237/
https://www.ncbi.nlm.nih.gov/pubmed/34881019
http://dx.doi.org/10.1177/20458940211059713
_version_ 1784610573097369600
author Luo, Ci-Jun
Qiu, Hong-Ling
Wu, Chang-Wei
He, Jing
Yuan, Ping
Zhao, Qin-Hua
Jiang, Rong
Wu, Wen-Hui
Gong, Su-Gang
Guo, Jian
Zhang, Rui
Liu, Jin-Ming
Wang, Lan
author_facet Luo, Ci-Jun
Qiu, Hong-Ling
Wu, Chang-Wei
He, Jing
Yuan, Ping
Zhao, Qin-Hua
Jiang, Rong
Wu, Wen-Hui
Gong, Su-Gang
Guo, Jian
Zhang, Rui
Liu, Jin-Ming
Wang, Lan
author_sort Luo, Ci-Jun
collection PubMed
description Cardiopulmonary exercise testing and pulmonary function test are important methods for detecting human cardio-pulmonary function. Whether they could screen vasoresponsiveness in idiopathic pulmonary artery hypertension (IPAH) patients remains undefined. One hundred thirty-two IPAH patients with complete data were retrospectively enrolled. Patients were classified as vasodilator-responsive (VR) group and vasodilator-nonresponsive (VNR) group on the basis of the acute vasodilator test. Pulmonary function test and cardiopulmonary exercise testing were assessed subsequently and all patients were confirmed by right heart catheterization. We analyzed cardiopulmonary exercise testing and pulmonary function test data and derived a prediction rule to screen vasodilator-responsive patients in IPAH. Nineteen of VR-IPAH and 113 of VNR-IPAH patients were retrospectively enrolled. Compared with VNR-IPAH patients, VR-IPAH patients had less severe hemodynamic effects (lower RAP, m PAP, PAWP, and PVR). And VR-IPAH patients had higher anaerobic threshold (AT), peak partial pressure of end-tidal carbon dioxide (P(ET)CO(2)), oxygen uptake efficiency (OUEP), and FEV(1)/FVC (P all <0.05), while lower peak partial pressure of end-tidal oxygen (P(ET)O(2)) and minute ventilation (VE)/carbon dioxide output (VCO(2)) slope (P all <0.05). FEV(1)/FVC (Odds Ratio [OR]: 1.14, 95% confidence interval [CI]: 1.02–1.26, P = 0.02) and PeakP(ET)CO(2) (OR: 1.13, 95% CI: 1.01–1.26, P = 0.04) were independent predictors of VR adjusted for age, sex, and body mass index. A novel formula (=−16.17 + 0.123 × PeakP(ET)CO(2) + 0.127×FEV(1)/FVC) reached a high area under the curve value of 0.8 (P = 0.003). Combined with these parameters, the optimal cutoff value of this model for detection of VR is −1.06, with a specificity of 91% and sensitivity of 67%. Compared with VNR-IPAH patients, VR-IPAH patients had less severe hemodynamic effects. Higher FEV(1)/FVC and higher peak P(ET)CO(2) were associated with increased odds for vasoresponsiveness. A novel score combining PeakP(ET)CO(2) and FEV(1)/FVC provides high specificity to predict VR patients among IPAH.
format Online
Article
Text
id pubmed-8647237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86472372021-12-07 PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension Luo, Ci-Jun Qiu, Hong-Ling Wu, Chang-Wei He, Jing Yuan, Ping Zhao, Qin-Hua Jiang, Rong Wu, Wen-Hui Gong, Su-Gang Guo, Jian Zhang, Rui Liu, Jin-Ming Wang, Lan Pulm Circ Original Research Article Cardiopulmonary exercise testing and pulmonary function test are important methods for detecting human cardio-pulmonary function. Whether they could screen vasoresponsiveness in idiopathic pulmonary artery hypertension (IPAH) patients remains undefined. One hundred thirty-two IPAH patients with complete data were retrospectively enrolled. Patients were classified as vasodilator-responsive (VR) group and vasodilator-nonresponsive (VNR) group on the basis of the acute vasodilator test. Pulmonary function test and cardiopulmonary exercise testing were assessed subsequently and all patients were confirmed by right heart catheterization. We analyzed cardiopulmonary exercise testing and pulmonary function test data and derived a prediction rule to screen vasodilator-responsive patients in IPAH. Nineteen of VR-IPAH and 113 of VNR-IPAH patients were retrospectively enrolled. Compared with VNR-IPAH patients, VR-IPAH patients had less severe hemodynamic effects (lower RAP, m PAP, PAWP, and PVR). And VR-IPAH patients had higher anaerobic threshold (AT), peak partial pressure of end-tidal carbon dioxide (P(ET)CO(2)), oxygen uptake efficiency (OUEP), and FEV(1)/FVC (P all <0.05), while lower peak partial pressure of end-tidal oxygen (P(ET)O(2)) and minute ventilation (VE)/carbon dioxide output (VCO(2)) slope (P all <0.05). FEV(1)/FVC (Odds Ratio [OR]: 1.14, 95% confidence interval [CI]: 1.02–1.26, P = 0.02) and PeakP(ET)CO(2) (OR: 1.13, 95% CI: 1.01–1.26, P = 0.04) were independent predictors of VR adjusted for age, sex, and body mass index. A novel formula (=−16.17 + 0.123 × PeakP(ET)CO(2) + 0.127×FEV(1)/FVC) reached a high area under the curve value of 0.8 (P = 0.003). Combined with these parameters, the optimal cutoff value of this model for detection of VR is −1.06, with a specificity of 91% and sensitivity of 67%. Compared with VNR-IPAH patients, VR-IPAH patients had less severe hemodynamic effects. Higher FEV(1)/FVC and higher peak P(ET)CO(2) were associated with increased odds for vasoresponsiveness. A novel score combining PeakP(ET)CO(2) and FEV(1)/FVC provides high specificity to predict VR patients among IPAH. SAGE Publications 2021-12-02 /pmc/articles/PMC8647237/ /pubmed/34881019 http://dx.doi.org/10.1177/20458940211059713 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Luo, Ci-Jun
Qiu, Hong-Ling
Wu, Chang-Wei
He, Jing
Yuan, Ping
Zhao, Qin-Hua
Jiang, Rong
Wu, Wen-Hui
Gong, Su-Gang
Guo, Jian
Zhang, Rui
Liu, Jin-Ming
Wang, Lan
PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
title PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
title_full PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
title_fullStr PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
title_full_unstemmed PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
title_short PeakP(ET)CO(2) combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
title_sort peakp(et)co(2) combined with fev1/fvc predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647237/
https://www.ncbi.nlm.nih.gov/pubmed/34881019
http://dx.doi.org/10.1177/20458940211059713
work_keys_str_mv AT luocijun peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT qiuhongling peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT wuchangwei peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT hejing peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT yuanping peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT zhaoqinhua peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT jiangrong peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT wuwenhui peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT gongsugang peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT guojian peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT zhangrui peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT liujinming peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension
AT wanglan peakpetco2combinedwithfev1fvcpredictsvasodilatorresponsivepatientswithidiopathicpulmonaryarterialhypertension